Personalised Cancer Medicine Flashcards 2022
Indications determined by the organ of origin
Prostate Cancer
Standard
Recommended
Currently not recommended
- BRCA1 and BRCA2*
- Microsatellite instability*
- HRR Profound panel* (somatic)
- Androgen receptor aberrations
- PDL1
- PTEN
* by either IHQ (MLH1, PMS2, MSH2 a MSH6) or by genomic study (BAT25 y BAT26, D2S123, D5S346 and D17S250).
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.
The Recommended category is based on currentrecommendations by EMEA and FDA.
References:
1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440.
2. To SQ, Kwan EM, Fettke HC, et al. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007.
3. Beltran H, Antonarakis ES, Morris MJ, Attard G. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. Am Soc Clin Oncol Educ Book. 2016;35:131-41. doi: 10.1200/EDBK_159248.
